Nov 19, 2025 • Motley Fool
NEUTRAL
Biotech Stock Gets Booted in Latest Fund Update
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Nov 17, 2025 • Benzinga
NEUTRAL
Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer - Nuvalent ( NASDAQ:NUVL )
Nuvalent, Inc. ( NASDAQ:NUVL ) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial. The study evaluated neladalkib in tyrosine kinase inhibitor ( TKI ) -pretreated patients with advanced ALK-positive non-small cell lung cancer ( NSCLC ) .
Nov 12, 2025 • Benzinga
SOMEWHAT-BULLISH
This Waste Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Atour Lifestyle Holdings ( NASDAQ:ATAT ) , Cintas ( NASDAQ:CTAS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Aug 19, 2025 • Benzinga
SOMEWHAT-BULLISH
This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - AeroVironment ( NASDAQ:AVAV ) , Celestica ( NYSE:CLS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Aug 07, 2025 • Motley Fool
NEUTRAL
Nuvalent ( NUVL ) Q2 R&D Up 65%
Nuvalent ( NASDAQ:NUVL ) , a clinical-stage biotechnology company developing therapies for cancers driven by kinase mutations, released its second quarter 2025 earnings results on August 7, 2025. There was no product revenue, consistent with expectations for a pre-commercial biotech.